Octreotide for malignant bowel obstruction: Twenty years after

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 3, 2012, Pages 388-392

  Mercadante, Sebastiano ^a,b   Porzio, Giampiero ^c  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Home care program ^*  (Italy)

Author keywords

Advanced cancer; Malignant bowel obstruction; Octreotide

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CHLORPROMAZINE; CORTICOSTEROID; DIATRIZOATE; METOCLOPRAMIDE; OCTREOTIDE; SCOPOLAMINE BUTYL BROMIDE; STEROID;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; AGITATION; ANOREXIA; COLIC; CONTINUOUS INFUSION; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SECRETION; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE OBSTRUCTION; MALIGNANT BOWEL OBSTRUCTION; NASOGASTRIC TUBE; NAUSEA; OVARY CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL TIME; SUSTAINED RELEASE PREPARATION; SYSTEMATIC REVIEW; TERMINAL DISEASE; VOMITING; XEROSTOMIA;

GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL OBSTRUCTION; NEOPLASM STAGING; NEOPLASMS; OCTREOTIDE; TREATMENT OUTCOME;

EID: 84861100621     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.12.006     Document Type: Review

References (21)

1. Baines M., Oliver D.J., Carter R.L. Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet 1985, ii:990-993.
2. Ventafridda V., Ripamonti C., Caraceni A., Spoldi E., Messina L., de Conno F. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990, 76:389-393.
3. De Conno F., Caraceni A., Zecca E., Spoldi E., Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 1991, 6:484-486.
4. Prommer E.E. Established and potential therapeutic applications of octreotide in palliative care. Support Care Cancer 2008, 16:1117-1123.
5. Mercadante S., Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage 1992, 7:496-498.
6. Khoo D., Riley J., Waxman J. Control of emesis in bowel obstruction in terminally ill patients. Lancet 1992, 339:375-376.
7. Mercadante S., Spoldi E., Caraceni A., Maddaloni S., Simonetti M.T. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993, 7:295-299.
8. Khoo D., Hall E., Motson R., Riley J., Denman K., Waxman J. Palliation of malignant intestinal obstruction. Eur J Cancer 1994, 30A:28-30.
9. Mangili G., Aletti G., Frigerio L., et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer 2005, 15:830-835.
10. Mercadante S. Bowel obstruction in home-care cancer patients: four years experience. Support Care Cancer 1995, 3:190-193.
11. Mangili G., Franchi M., Mariani A., et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996, 61:345-348.
12. Mercadante S., Ripamonti C., Casuccio A., Zecca E., Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000, 8:188-191.
13. Ripamonti C., Mercadante S., Groff L., Zecca E., De Conno F., Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000, 19:23-34.
14. Mystakidou K., Tsilika E., Kalaidopoulou O., Chondros K., Georgaki S., Papadimitriou L. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res 2002, 22:1187-1192.
15. Mercadante S., Ferrera P., Villari P., Marrazzo A. Aggressive pharmacological treatment for reversing bowel obstruction. J Pain Symptom Manage 2004, 28:412-416.
16. Shima Y., Ohtsu A., Shirao K., Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol 2008, 38:354-359.
17. Hisanaga T., Shinjo T., Morita T., et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 2010, 40:739-745.
18. Porzio G., Aielli F., Verna L., et al. Can malignant bowel obstruction in advanced cancer patients be treated at home?. Support Care Cancer 2011, 19:431-433.
19. Weber C., Zulian G.B. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics. Am J Hosp Palliat Care 2009, 26:84-88.
20. Matulonis U.A., Seiden M.V., Roche M., et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 2005, 30:563-569.
21. Massacesi C., Galeazzi G. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction. Palliat Med 2006, 20:715-716.